TID 1000 mg Mesalazine Versus TID 2x500 mg Mesalazine in Active Ulcerative Colitis (UC)
Status:
Completed
Trial end date:
2015-06-01
Target enrollment:
Participant gender:
Summary
The purpose of the trial is to proof whether TID 1000 mg mesalazine is non-inferior to TID 2x
500 mg mesalazine in the treatment of patients with acute ulcerative colitis